Biogen Idec

Summary

Biogen Idec appeared to be the Corporate Investor, which was created in 1978. The main office of represented Corporate Investor is situated in the Weston. The venture was found in North America in United States.

Among the various public portfolio startups of the fund, we may underline Samsung Bioepis, Vivoryon Therapeutics, Neurimmune Holding The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Biopharma, Medical Device.

The current fund was established by Bernard Mach, Jeff Behrens, Phillip Sharp.

Considering the real fund results, this Corporate Investor is 12 percentage points more often commits exit comparing to other organizations. This Biogen Idec works on 28 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2009. The fund is constantly included in less than 2 investment rounds annually. When the investment is from Biogen Idec the average startup value is more than 1 billion dollars. The top amount of exits for fund were in 2017.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Biogen Idec, startups are often financed by Warburg Pincus, Mayfield Fund, Abingworth. The meaningful sponsors for the fund in investment in the same round are SR One, U.S. Venture Partners (USVP), Partners HealthCare. In the next rounds fund is usually obtained by SR One, MPM Capital, Kleiner Perkins.